Related Experiment Video

Updated: Jun 20, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Treatment of liver fibrosis: clinical aspects

P Calès1, J Boursier, J Chaigneau

  • 1Service d'hépatogastroentérologie, CHU, 49933 Angers cedex 09, France. paul.cales@univ-angers.fr

Gastroenterologie Clinique Et Biologique
|September 1, 2009
PubMed

Insights

Antifibrotic treatments aim to manage chronic liver disease complications by targeting fibrosis progression. Sartans, targeting the renin-angiotensin system, show promise in antifibrotic therapy.

Area of Science:

  • Hepatology
  • Fibrosis Research
  • Pharmacology

Background:

  • Chronic liver disease management focuses on preventing complications when the underlying cause is untreatable.
  • Antifibrotic therapies aim to modify fibrosis by directly impacting its mechanisms.
  • Key therapeutic targets include the disease cause, comorbidities, and the fibrosis itself.

Purpose of the Study:

  • To define antifibrotic treatment and its therapeutic endpoints.
  • To outline methods for monitoring fibrosis progression.
  • To identify potential therapeutic targets and drug classes for antifibrotic therapy.

Main Methods:

  • Review of antifibrotic treatment modalities (fibrosis reduction, reversion).
  • Utilizing semiquantitative histological staging and morphometry for fibrosis monitoring.
  • Defining non-response based on fibrosis progression rates.

Main Results:

  • Antifibrotic treatment can target fibrosis course, reversion, or cirrhosis reversion.
  • Fibrosis progression, not static measurements, is crucial for monitoring treatment efficacy.
  • The renin-angiotensin system, targeted by sartans, is a promising candidate for antifibrotic treatment.

Conclusions:

  • Antifibrotic treatments are essential for managing untreatable chronic liver diseases.
  • Accurate monitoring of fibrosis progression is key to assessing treatment effectiveness.
  • Sartans represent a potential therapeutic strategy, with ongoing trials and development of new drugs.

More Related Videos

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...